New triple-threat weapon needed in war between man and microbe

March 24, 2008
New triple-threat weapon needed in war between man and microbe
Without a breakthrough, microbial resistance might be inevitable in humanity's struggle against infectious disease, a medicinal chemist reports. Above is a color-enhanced scanning electron micrograph showing Salmonella typhimurium (red) invading cultured human cells. Courtesy of National Institute of Allergy and Infectious Diseases of the NIH

Mankind’s age-old battle against infectious diseases stands to rage on and on, unless scientists develop a new generation of triple-action antibiotics, according to an article scheduled for the March 28 issue of ACS’ monthly Journal of Natural Products.

In the article, Lester A. Mitscher presents a “rather personalized” account of the turbulent tug-of-war between microbes and mankind, describing past tactics, lessons learned, and a cautious prediction about the road ahead.

Mitscher notes, for instance, that “miracle drugs” in the 1940s and ’50s failed to live up to expectations. Though penicillin promised an end to infections worldwide in 1941, reports of resistant bacteria appeared only a year later. “Significant clinical resistance is now known for virtually all antibiotics in medical use,” the article states. “Unfortunately, the problem is getting worse since big pharma has largely withdrawn from research directed toward new antibiotic discovery.”

The review concludes that microbial resistance is inevitable pending unforeseen breakthroughs. One involves development of new antibiotics that go beyond killing or slowing the growth of disease-causing microbes. Those new medications would contain antimutagenic ingredients that discourage bacteria from mutating into resistant forms. In addition, they would pack immunostimulants that enlist the body’s own immune defense system to fight off an infection.

“Continued close observation and exploitation of natural phenomena appear at present to be the wisest course for scientists to follow in trying to deal with this problem,” says Mitscher.

Source: ACS

Explore further: Researchers propose rapid Ebola test using nanotechnology

Related Stories

Researchers propose rapid Ebola test using nanotechnology

November 13, 2015

Just as Ebola was finally fading from the headlines, it came back in the news with shocking reports: a Scottish nurse rehospitalized nine months after beating Ebola is now suffering from meningitis caused by the virus. A ...

Cells get noisy in crowded environments

October 27, 2015

Bacteria are incredibly small, yet pack an enormous diversity of different molecules such as DNA, mRNA and proteins. Chemists from Radboud University Nijmegen, Eindhoven and Paris now show for the first time that random variations ...

Recommended for you

NASA's space-station resupply missions to relaunch

November 29, 2015

NASA's commercial space program returns to flight this week as one of its private cargo haulers, Orbital ATK, is to launch its first supply shipment to the International Space Station in more than 13 months.

CERN collides heavy nuclei at new record high energy

November 25, 2015

The world's most powerful accelerator, the 27 km long Large Hadron Collider (LHC) operating at CERN in Geneva established collisions between lead nuclei, this morning, at the highest energies ever. The LHC has been colliding ...


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Mar 24, 2008
triple-action antibiotics? First we`d better see a quadruple-action antibiotic policy in place worldwide, aimed at ensuring proper use of antibiotics, as from what i understand there is too much abuse of antibiotic use as it is, in a sense that it is relied on too much and it is improperly used...
not rated yet Mar 25, 2008
Currently drug companies develop drugs that can be patented and sold at a large markup to cover R&D costs and generate a profit.

Perhaps it would be better if society could put out a large bounty on drug treatments for all diseases in proportion to what curing or controling them is worth to society and only allow this bounty to be collected upon meeting specific demands for efficacy, safety and at the expense of not patenting the drug. That would allow society a good measure of control over which diseases are targeted by drug companies.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.